RabMAb

Anti-Cdk4 antibody [EPR4513] (ab108355)

Overview

  • Product nameAnti-Cdk4 antibody [EPR4513]
    See all Cdk4 primary antibodies
  • Description
    Rabbit monoclonal [EPR4513] to Cdk4
  • Tested applicationsWB, ICC/IFmore details
  • Species reactivity
    Reacts with: Human

    Does not react with

    Mouse, Rat
  • Immunogen

    A synthetic peptide corresponding to residues on the C terminus of Human Cdk4.

  • Positive control
    • WB: HeLa, MCF7 and K562 cell lysates ICC/IF: HeLa cells
  • General notes

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A 40 µl trial size is available to purchase for this antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab108355 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 34 kDa (predicted molecular weight: 34 kDa).
ICC/IF 1/100 - 1/250.
  • Application notesIs unsuitable for Flow Cyt,IHC-P or IP.
  • Target

    • FunctionSer/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
    • Involvement in diseaseDefects in CDK4 are a cause of susceptibility to cutaneous malignant melanoma type 3 (CMM3) [MIM:609048]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
    • Sequence similaritiesBelongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications
      Phosphorylation at Thr-172 is required for enzymatic activity. Phosphorylated, in vitro, at this site by CCNH-CDK7, but, in vivo, appears to be phosphorylated by a proline-directed kinase. In the cyclin D-CDK4-CDKN1B complex, this phosphorylation and consequent CDK4 enzyme activity, is dependent on the tyrosine phosphorylation state of CDKN1B. Thus, in proliferating cells, CDK4 within the complex is phosphorylated on Thr-172 in the T-loop. In resting cells, phosphorylation on Thr-172 is prevented by the non-tyrosine-phosphorylated form of CDKN1B.
    • Cellular localizationCytoplasm. Nucleus. Membrane. Cytoplasmic when non-complexed. Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress through G(1) phase. The complex accumulates on the nuclear membrane and enters the nucleus on transition from G(1) to S phase. Also present in nucleoli and heterochromatin lumps. Colocalizes with RB1 after release into the nucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • Cdk 4 antibody
      • cdk4 antibody
      • CDK4 protein antibody
      • CDK4_HUMAN antibody
      • Cell division kinase 4 antibody
      • Cell division protein kinase 4 antibody
      • CMM 3 antibody
      • CMM3 antibody
      • Crk3 antibody
      • Cyclin dependent kinase 4 antibody
      • Cyclin-dependent kinase 4 antibody
      • Melanoma cutaneous malignant 3 antibody
      • MGC14458 antibody
      • p34 cdk4 antibody
      • PSK J3 antibody
      • PSK-J3 antibody
      see all

    Anti-Cdk4 antibody [EPR4513] images

    • All lanes : Anti-Cdk4 antibody [EPR4513] (ab108355) at 1/1000 dilution

      Lane 1 : Human osteosarcoma cells - control, non-targeting siRNA
      Lane 2 : Human osteosarcoma cells - siRNA for CDK4

      Lysates/proteins at 20 µg per lane.

      Secondary
      HRP-conjugated goat anti-rabbit IgG polyclonal at 1/2000 dilution
      developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 34 kDa
      Observed band size : 34 kDa


      Exposure time : 5 seconds

      This image is courtesy of an Abreview submitted by Sonia Rocha

      See Abreview

    • All lanes : Anti-Cdk4 antibody [EPR4513] (ab108355) at 1/1000 dilution

      Lane 1 : Hela cell lysate
      Lane 2 : MCF7 cell lysate
      Lane 3 : K562 cell lysate

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 34 kDa
    • ab108355, at a 1/100 dilution, staining Cdk4 in HeLa cells by Immunofluorescence.

    References for Anti-Cdk4 antibody [EPR4513] (ab108355)

    ab108355 has not yet been referenced specifically in any publications.

    Product Wall

    Application Western blot
    Loading amount 20 µg
    Gel Running Conditions Reduced Denaturing (10%)
    Sample Human Cell lysate - whole cell (osteosarcoma cells)
    Specification osteosarcoma cells
    Treatment lane 1 control, lane 2 siRNA for CDK4, 48h
    Blocking step Milk as blocking agent for 10 minute(s) · Concentration: 10% · Temperature: 21°C
    Username

    Dr. Sonia Rocha

    Verified customer

    Submitted Sep 26 2014

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"